Novel Approaches to Metastatic HER2+ Breast Cancer

Article

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.

Considerations in Metastatic HER2+ Breast Cancer
Tuesday, October 13, 2020
8:00 PM-9:30 PM CDT

Pre-register and attend this event to be eligible to win an Apple Watch!

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD.

Topics of discussion at this virtual event include:

  • Review and evaluate data on recent therapeutic advances in metastatic HER2+ breast cancer
  • Discuss clinical challenges and areas of uncertainty faced when selecting later lines of therapy for patients with metastatic HER2+ breast cancer
  • Identify factors that influence treatment selection and planning for patients with metastatic HER2+ breast cancer

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

​ Speakers:​ ​ ​ ​ ​

Debu Tripathy, MD

Professor and Chair,
Department of Breast Medical Oncology
UT MD Anderson Cancer Center
Houston, Texas

Michelina Cairo, MD

Texas Oncology
Houston, TX
United States

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Related Videos
Shruti Tiwari, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Shruti Tiwari, MD
Nan Chen, MD
Julia Foldi, MD, PhD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD